This study was designed to see if immunosuppression achieved using local application of cyclosporine A (Cs. A) or CD4 and CD8 antibodies would improve bone formation following intramuscular injections of human BMP-4 and BMP-9 adenoviral vectors (ADhBMP4 and ADhBMP9) in Sprague-Dawley rats. Cs. A was injected into the thigh muscle. After 2 days, ADhBMP4, ADhBMP9, and the antibodies were separately injected into the left and right rear legs. At this time, the number of CD4+/CD3+ cells was significantly lower and the number of CD8+/CD3+ cells higher in the Cs. A group than in the control group (Po0.01). The total number of white blood cells 3 days following injection of CD4 and CD8 antibodies was significantly lower than that before the injection (Po0.01). At 4 weeks after the viral and antibody injections, mean bone volumes at the ADhBMP9 treatment sites were 0.2970.01 cm 3 in the viral control group, 0.1770.03 cm 3 in the Cs. A-ADhBMPs group, and 0.5970.07 cm 3 in the antibodies-ADhBMPs group. ADhBMP4 did not induce new bone formation in any group. This study demonstrates that local immunomodulation may improve the osteogenic potential of bone morphogenetic protein gene therapy in the clinical setting.
Introduction
Bone morphogenetic proteins (BMPs) are members of the transforming growth factor b (TGF-b) superfamily. At present, more than 30 BMPs have been discovered. 1 Some members of the BMP family are also known as osteogenic proteins (OPs), growth/differentiation factors (GDFs), and cartilage-derived morphogenetic proteins (CDMPs). 2 Some BMPs have significant osteogenic potential in vitro and in vivo; indeed, BMP-2 has recently been approved by the Food and Drug Administration for use in spinal fusion procedures in humans. 3, 4 Nevertheless, many factors, such as the need for high doses and specialized carrier systems, have limited the use of BMPs in the daily practice of orthopedic and neurological surgery. 5 Gene therapy techniques are being developed to enhance local expression of osteogenic BMPs and to induce local bone formation. The BMP genes that have been used in previous gene therapy studies include BMP-2, -4, -6, -7, and -9. 6, 7 The viral vectors used to deliver these genes, either directly or through ex vivo techniques, include adenoviruses, retroviruses, and adeno-associated viruses. 8, 9 Adenoviral vectors containing any of the aforementioned BMP genes have been shown to have significant osteogenic potential in immunodeficient animals. In immunocompetent animals, however, the osteogenic activity of BMP adenoviral vectors is significantly reduced. 6, 10, 11 Efforts are currently being directed toward improving the osteogenic potential of BMP gene therapy in immunocompetent animals.
The development of immunosuppressive agents for organ transplantation may provide novel tools to improve the efficacy of BMP gene therapy. [11] [12] [13] [14] The use of short-term, local immunosuppression may improve the biologic activity of BMP vectors and reduce the side effects of immunosuppression because the bone formation process can be initiated by very brief exposures to BMP. 15, 16 From an immunological point of view, the T-cell defect in athymic nude animals is the major factor separating these animals from immunocompetent ones. Therefore, T-cell functions are critical factors that determine the different osteogenic potentials of BMP adenoviral vectors in immunodeficient and immunocompetent animals. This suggests that immunosuppressive agents that have an inhibitory effect on T cells may improve the efficacy of BMP gene therapy. Cyclosporine A (Cs. A) is a cyclic undecapeptide that was originally isolated from Tolypocladium inflatum Gams and is commonly used as an immunomodulatory agent in the treatment of patients receiving allogeneic organ transplants. The major pharmacological effect of Cs. A is the inhibition of early events in the activation of T cells by antigens. These T cells regulate B cells, macrophages, and other cells through the secretion of cytokines and chemokines. 13, 14, 17, 18 Therefore, Cs. A may be an ideal agent to improve bone formation induced by BMP adenoviral vectors.
Cell surface markers are basic characteristics used to distinguish the various types of immune cells. CD4 is a surface marker that is mainly expressed by helper T cells, but is also expressed by macrophages, natural killer cells, and dendritic cells. CD8 is a surface marker of the cytotoxic T lymphocyte, one of the major cell types involved in the clearance of foreign agent-transduced cells. Local delivery of CD4 and CD8 antibodies may temporarily interrupt host immune responses to adenoviral vectors, increase the length and level of transgene expression, and lead to increased osteogenesis without significantly affecting the immune capabilities of the entire system.
Our previous studies of human BMP-4 and BMP-9 adenoviral vectors (ADhBMP4 and ADhBMP9) have demonstrated that these vectors have similar osteogenic potentials in athymic nude rats, but their activities are significantly different in immunocompetent animals. 6, 19 ADhBMP4 does not induce bone formation in immunocompetent rats. ADhBMP9 can produce significant osteogenesis in these animals, but the new bone volumes are smaller than those generated in immunodeficient animals. The reasons for the difference in in vivo osteogenic activity between these two BMP vectors is not clearly known, but may be related to different types of receptors and signal transduction pathways. [20] [21] [22] [23] In the present study, we tested the effects of Cs. A and those of CD4 and CD8 antibodies on the osteogenic activity of ADhBMP4 and ADhBMP9 following a direct intramuscular injection in Sprague-Dawley rats.
Results
To assess the activities of local delivery of immunosuppressive agents in rats, total numbers of white blood cells (WBCs), percentages of different T cells, and titers of adenovirus-neutralizing antibody were measured. Bone volumes were quantified using computerized tomography (CT) to assess the effects of two types of immunosuppressive agents on the process of bone formation induced by ADhBMP4 and ADhBMP9 in immunocompetent rats.
A total of twenty-five 2-month-old Sprague-Dawley rats were used in this study. The rats were randomly separated into five groups with five rats in each group. Table 1 shows that the rats were treated and tested at different time points.
Analysis of WBCs
The total number of WBCs was determined at different time points (Table 2 ). On day 6, the number of WBCs was significantly lower in the CD4 and CD8 antibodies group (Group 4; 58857760/ml) and in the antibodies plus ADhBMPs group (Group 5; 60507389/ml) than that determined on day 1 prior to treatment (84557603/ml in Group 4 (P ¼ 0.04) and 89457623/ml in Group 5 (Po0.01)). In the other groups and at different time points, the numbers were not significantly different and lay within the normal range. This result indicates that local intramuscular delivery of mouse anti-rat CD4 and 
Titers of adenovirus-neutralizing antibody in different groups
The titer of adenovirus-neutralizing antibody was defined as the serum dilution level at which there was a 97% inhibition of the adenovirus. All titers of adenovirus-neutralizing antibody measured in animals before viral injection and in animals after they were given Cs. A (Group 2) or antibodies (Group 4) were lower than 20 times dilution (the lowest serum dilution). The mean titers of adenovirus-neutralizing antibody on days 16 and 30 were, respectively, 289792 and 4347119 in the viral control group (Group 1), 244750 and 364751 in the Cs. A with ADhBMPs group (Group 3), and 103720 and 124724 in the CD antibodies with ADhBMPs group (Group 5) (Figure 2 ). On day 30, the titers of adenovirus-neutralizing antibodies were significantly lower in the group also given CD4 and CD8 antibodies (Group 5) than in the viral control group (Group 1).
Bone volumes induced by ADhBMP4 and ADhBMP9 in different groups
No bone formation in the thigh muscle was demonstrated in any rat in the negative control groups (Groups 2 and 4). In addition, there was no evidence of bone formation at the ADhBMP4 injection site in the rats in Groups 1, 3, and 5. Nevertheless, on day 30, bone formation was found at the ADhBMP9 injection site in all the rats in Groups 1, 3, and 5. Figure 3 shows twodimensional CT scans and three-dimensional reconstructions of ectopic bone formation in different groups. Figure 4 shows the volumes of ADhBMP9-induced bone in the various groups. The mean volumes of bone induced by ADhBMP9 were 0.2970.01 cm 3 in animals given only the BMP vector (Group 1), 0.1770.03 cm 3 in animals given Cs. A and the BMP vector (Group 3), and 0.5970.07 cm 3 in animals given CD4 and CD8 antibodies and the BMP vector (Group 5). When bone volumes in the groups that received immunosuppressive agents were compared with those in the viral control group, the probability value was 0.03 for the Cs. A group and less than 0.01 for the antibodies group (Scheffé's method applied after single-factor analysis of variance 17, 18 These cytokines play an important role in the regulation of bone metabolism. [24] [25] [26] For example, IL-1, tumor necrosis factor (TNF)-a, and TNF-b are potent stimulators of bone resorption and also affect osteoblast metabolism. INF-g preferentially inhibits cytokine-stimulated resorption of bone. [27] [28] [29] [30] [31] The role that cytokines play in the process of BMP-induced bone formation is currently not clear. Unpublished results from our laboratory have shown that some of the components of serum, especially following adenoviral vaccination, can strongly inhibit the alkaline phosphatase activities in C2C12 cells treated with BMP-2, BMP-6, and BMP-9. Some reports have also shown that high dose (415 mg/kg) and long-term Cs. A treatment significantly increases bone resorption in rats. 24, 32, 33 This may be relevant to the Cs. A-induced decrease in ADhBMP9 bone induction because a dose of 40 mg/kg Cs. A was used in this study.
The mechanisms of action of Cs. A have been shown to occur through several binding proteins, including cyclophilins, serine/threonine phosphatase, and calcineurin. Evidence suggests that cyclophilins regulate NF-AT, AP-3, and NF-kB. Furthermore, the activity of NF-kB is regulated in a complex fashion that includes phosphorylation and dephosphorylation events. There may be crosstalk between these signaling pathways and the signal transduction pathways activated by BMPs. 34, 35 Both Type I and Type II BMP receptors are serine/ threonine kinases. The Type II receptors are constitutive active serine/threonine kinase receptors. The Type I receptor is activated by the Type II receptor by phosporylation at the GS box, a juxtamembrane domain rich in glycines and serines. 20 Calcineurin usually functions as a Ca 2+ -and calmodulin-dependent complex, but calmodulin may not be involved in complexes with cyclophilin. Calmodulin can bind Smads 1 through 4 in a calcium-dependent manner. Data from some studies indicate that calmodulin inhibits the activin signals and stimulates the BMP signal. Other studies have shown that calmodulin inhibits Smad activities. 36, 37 In summary, there are most likely complex interactions between BMP-induced bone formation pathways and the molecular pathways involved in the activity of Cs. A.
Immunosuppressive agents can be used not only to increase the osteogenic activity of BMP gene therapy but also to elucidate the complex relationship between the BMP signaling pathways and the host immune response. One research group has reported that both cyclophosphamide and fujimycin (FK-506) enhanced bone formation induced by BMP-2 and by ADhBMP2. 11, 12, 38 Although FK-506 is an immunosuppressive agent closely related to Cs. A, the different effects of Cs. A on ADhBMP4 and ADhBMP9 gene therapy and those of FK-506 on ADhBMP2 gene therapy may involve different BMP receptors and signal transduction pathways or the different binding proteins of the two immunosuppressive agents. Recent advances in immunomodulation provide a wide choice of immunosuppressive agents for both direct and ex vivo gene therapy. The ideal immunosuppressive agent used in this field should exhibit temporary, specific, and local immunosuppressive effects. As bone induction can be initiated in 2-7 days in animals following BMP delivery, the potential risks of the immunosuppressive approach should be minimal and this approach may be practical in the clinical setting. Since there is a very complex relationship between the process of bone formation and the animal immune system, it should be paid more attention in future studies.
In conclusion, in this study, we demonstrated that Cs. A and CD4 and CD8 antibodies have immunosuppressive functions. Cs. A inhibits bone formation induced by ADhBMP9, whereas the antibodies significantly improve the volume of bone formation induced by this BMP vector. The impact of the two kinds of immunosuppressive agents on ADhBMP4 remains unclear, however, because no new bone was observed in any animal after administration of ADhBMP4.
Materials and methods

Immunosuppressive agents and adenoviral vectors
Mouse anti-rat CD4 and CD8 antibodies were purchased from Research Diagnostics. Inc. (Flanders, NJ, USA), and Cs. A was obtained from Sigma Chemical Co. (St Louis, MO, USA). To simplify the experimental design and reduce the number of animals that were used, relatively high doses of immunosuppressive agents were chosen: 40 mg/kg for each CD4 and CD8 antibody and 40 mg/kg for Cs. A. 39, 40 ADhBMP4 and ADhBMP9 were constructed, produced, purified, and titrated in a manner Local immunomodulation improves osteogenesis JZ Li et al previously reported. 6, 16 The measured titer of ADhBMP4 was 4 Â 10 9 plaque-forming units (PFU)/ml (2.12 Â 10 12 particles/ml) and the titer of ADhBMP9 was 1.5 Â 10 9 PFU/ml (4.38 Â 10 11 particles/ml). Based on our published data and previous experimental results, a dose of 10 7 PFU for both ADhBMP4 and ADhBMP9 may induce a large size of ectopic bone in athymic nude rats. Doses of ADhBMP9 between 10 7 and 5 Â 10 7 PFU can induce a large size of bone in immunocompetent rats, but doses of ADhBMP4 between 10 7 and 5 Â 10 8 PFU cannot induce any bone formation in immunocompetent animals. 6, 15, 16, 19, 23 A medium dose of ADhBMP9 (1.5 Â 10 7 PFU) or ADhBMP4 (1.2 Â 10 8 PFU) was used in this study.
Animal groups and injections
In total, twenty-five 2-month-old Sprague-Dawley rats were used in this study. The rats were randomly separated into the following five groups with five rats in each group (Table 1) : Group 1, ADhBMP4 and ADhBMP9; Group 2, Cs. A; Group 3, Cs. A with ADhBMP4 and ADhBMP9; Group 4, mouse anti-rat CD4 and CD8 antibodies; and Group 5, mouse anti-rat CD4 and CD8 antibodies with ADhBMP4 and ADhBMP9. On day 1, blood was collected from the tail vein of each animal and immediately mixed with heparin. In the rats in Groups 2 and 3, Cs. A (40 mg/ kg) was injected into the thigh musculature on both sides. On day 3, blood samples were first collected from all animals and the rats received the following injections in the front thigh muscles with the needle touching the femur: Group 1 and 3, ADhBMP4 in the left thigh (1.2 Â 10 8 PFU/70 ml) and ADhBMP9 in the right thigh (1.5 Â 10 7 PFU/70 ml); Group 2, phosphate-buffered saline (PBS; 70 ml) in each thigh; Group 4, mouse anti-rat CD4 and CD8 antibodies in each thigh (10 mg/10 ml CD4 plus 10 mg/10 ml CD8 with 50 ml PBS); and Group 5, mouse anti-rat CD4 and CD8 antibodies plus ADhBMP4 in the left thigh and ADhBMP9 in the right thigh (5 mg/ 5 ml CD4 plus 5 mg/5 ml CD8 plus 50 ml ADhBMP4 or ADhBMP9). Blood samples were again collected on days 6, 10, 16, and 30.
Analysis of WBCs
Total numbers of WBCs were measured on days 1, 3, 6, 10, and 16 as a standard procedure. Briefly, 10 ml of blood was added to 1 ml red blood cell (RBC) lysis buffer (ACK buffer: 150 mmol/l NH 4 Cl, 61 mmol/l KHCO 3 , and 1 mmol/l Na 2 EDTA, pH 7.3). 41 The total number of WBCs was counted on a hemacytometer and the number of cells per microliter was calculated.
Determining levels of CD3+, CD4+, and CD8+ cells
The procedures used to isolate and stain WBCs were identical to those previously reported. 16 Briefly, 100 ml of blood was suspended in 1 ml PBS. In total, 9 ml of distilled water was added to the blood to lyse the RBCs. After 30 s, 1 ml of 10-fold concentrated PBS was added to each tube. The WBCs were isolated after centrifugation and stained with mixed antibodies against CD3 (fluorescein isothiocyanate (FITC)), CD4 (allophycocyanin (APC)), and CD8 (tricolor (TC)) (Caltag Laboratories, Burlingame, CA, USA) in 200 ml PBS for 12 h at 41C. The stained WBCs were washed with PBS and measured using flow cytometry. The percentages of CD3+, CD4+/ CD3+, and CD8+/CD3+ cells were calculated and compared among the various animal groups on days 3 and 6 by using the one-way ANOVA multiple-comparison method.
Measuring adenovirus-neutralizing antibody titers
Rat sera collected on days 1, 16, and 30 were tested for adenovirus-neutralizing antibody. 16 The sera were serially diluted in 250 ml Dulbecco minimal Eagle medium with 10% fetal bovine serum at a dilution factor of 2 from 20-to 640-fold and mixed with equal volumes of viral solution containing 500 green cell-forming units (GFU) of recombinant green fluorescent protein adenovirus (ADCMVGFP). The mixture was incubated at 371C for 1 h and added to 96-well plates containing confluent 293 cells. Four wells were used for each concentration with 100 ml/100 GFU/well. The plates were incubated at 371C in an atmosphere of 95% air/5% CO 2 for 24 h. The total numbers of green cells in four wells of each concentration were counted to obtain the three serum dilutions with the lowest numbers of green cells. The resulting green cell numbers were used in regression analyses. The curves and equations were used to calculate the neutralizing antibody titer in sera. The titer of adenovirus-neutralizing antibody was defined as the serum dilution that resulted in a 97% inhibition of ADCMVGFP. A comparison of titers among groups on days 16 and 30 was accomplished using the one-way ANOVA multiplecomparison method.
CT imaging analysis of ectopic bone formation
All rats were scanned by CT using a Picker PQ 6000 scanner on day 30. Axial images with a 1-mm collimation and a 1-mm table increment were obtained using the standard algorithm with 130 kV, 100 mA, a 2-s scan time, and a 40-mm image size. Three-dimensional reconstructions and evaluations of bone volumes were performed with the aid of a Voxel Q workstation. Bone volumes on day 30 were compared using one-way ANOVA followed by the Scheffé method of comparing contrasts.
Histological analysis
The rats were euthanized on day 32. The injection sites in the thigh muscles were removed and fixed in 10% neutral-buffered formalin. The thigh muscle samples were decalcified, embedded in paraffin, and cut into sections, after which the sections were placed on slides. The slides were then stained with hematoxylin and eosin and Masson trichrome.
